Welcome to our dedicated page for Liquidia Corporation SEC filings (Ticker: LQDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking Liquidia’s clinical milestones can feel like navigating a labyrinth of FDA language, trial statistics, and licensing footnotes. Each new Liquidia 8-K material events explained notice might include pivotal updates on YUTREPIA’s path to approval, while a single Form 4 could show an insider buying shares ahead of a data read-out. Our AI-driven platform decodes those complexities so you can focus on what matters, delivering Liquidia SEC filings explained simply the moment they hit EDGAR.
Stop skimming hundred-page PDFs. Stock Titan’s engine extracts the cash-runway tables from every Liquidia quarterly earnings report 10-Q filing, highlights trial spend buried inside the Liquidia annual report 10-K simplified, and flags Liquidia proxy statement executive compensation details side by side with peer data. Need to watch executive moves? Receive Liquidia Form 4 insider transactions real-time alerts that list each Liquidia executive stock transactions Form 4 in context—share price, option type, and historical buying patterns.
Whether you’re comparing treprostinil royalty streams or assessing dilution risk from future capital raises, our coverage spans every filing type—from 10-K, 10-Q, and 8-K to Section 16 reports—updated in seconds. AI-powered summaries, keyword search across historical documents, and exportable tables let you perform rapid Liquidia earnings report filing analysis without specialized training. Use cases include:
- Monitoring Liquidia insider trading Form 4 transactions before trial announcements
- Understanding Liquidia SEC documents with AI for quicker valuation models
- Tracking manufacturing scalability disclosures tied to PRINT® technology
Liquidia Corporation (NASDAQ:LQDA) filed a Form 8-K to disclose the receipt of an additional USD 50 million under the Sixth Amendment to its Revenue Interest Financing Agreement with HealthCare Royalty Partners IV, L.P. (HCR).
The funds became available after two key milestones satisfied the agreement’s “Funding Condition”:
- May 30 2025: The U.S. District Court for the Middle District of North Carolina denied United Therapeutics Corporation’s request for a preliminary injunction and temporary restraining order against Liquidia.
- June 2 2025: Liquidia completed its first commercial shipment of YUTREPIA™ (treprostinil inhalation powder) for treatment of PAH and PH-ILD.
The company now has access to a cumulative USD 100 million under the HCR facility (USD 50 million drawn in March plus the new USD 50 million). A further USD 25 million tranche remains available if: (1) YUTREPIA net sales exceed USD 100 million by June 30 2026 and (2) both parties mutually agree to fund.
No earnings data were provided, and the filing contains no new financial statements. The disclosure highlights strengthened liquidity to support YUTREPIA’s commercial rollout while acknowledging ongoing—but presently unsuccessful—litigation efforts by a competitor.
Insider Trading Alert: Liquidia Corp (LQDA) Director Raman Singh received 18,396 Restricted Stock Units (RSUs) on June 17, 2025. The RSUs were granted at $0 cost and convert to common stock on a one-for-one basis.
Key Details:
- Following the transaction, Singh directly owns 38,755 shares
- The RSUs vest at the earlier of: one-year anniversary of grant date or day before next annual shareholder meeting
- Transaction was reported via Form 4 filing on June 28, 2025
- Filing location: 419 Davis Drive, Suite 100, Morrisville, NC
This equity grant appears to be part of standard director compensation arrangements. The transaction increases Singh's alignment with shareholder interests through expanded equity ownership in the company.
Director Katherine Rielly-Gauvin of Liquidia Corp (LQDA) reported the acquisition of 18,396 restricted stock units (RSUs) on June 17, 2025. The RSUs were granted at $0 cost and convert to common stock on a one-for-one basis.
Key details of the transaction:
- Following the transaction, Rielly-Gauvin directly owns 38,755 shares
- The RSUs vest at the earlier of: - One-year anniversary of grant date - Day before next annual shareholder meeting
- Transaction was reported within the required filing deadline
This equity grant appears to be part of the company's director compensation program, representing a standard annual stock award to align the director's interests with shareholders.
Paul B. Manning, Director of Liquidia Corp (LQDA), reported multiple beneficial ownership positions and a new acquisition of company securities on June 17, 2025. Manning received 18,396 restricted stock units (RSUs) that convert to common stock on a one-for-one basis, with vesting occurring at the earlier of one-year from grant or the day before the next annual shareholder meeting.
Manning's total beneficial ownership includes:
- 816,311 shares through BKB Growth Investments LLC
- 435,674 shares through PBM Capital Finance LLC
- 1,101,665 shares in PBM 2024 Grantor Retained Annuity Trust
- 898,335 shares in Paul B. Manning Revocable Trust
- 3,131,794 shares held jointly with spouse
- 38,755 shares held directly (including new RSUs)
Total beneficial ownership across all entities amounts to approximately 6.42 million shares, indicating significant insider ownership position in the company.
Director Arthur S. Kirsch of Liquidia Corp reported acquiring 18,396 Restricted Stock Units (RSUs) on June 17, 2025. The RSUs were granted at $0 cost and convert to common stock on a one-for-one basis.
Key details of the transaction:
- The RSUs will vest at the earlier of: one-year anniversary of grant date or day before next annual shareholder meeting
- Following the transaction, Kirsch owns 40,755 shares directly and 30,000 shares indirectly through a revocable trust
- Total beneficial ownership after transaction: 70,755 shares
This Form 4 filing indicates ongoing equity-based compensation for board members, aligning director interests with shareholders through stock ownership. The transaction was reported within the required timeframe under SEC regulations.
Liquidia Corporation (LQDA) – Form 4 insider filing
Director Dr. Joanna Horobin reported the grant of 18,396 restricted stock units (RSUs) on 17 June 2025. The award was coded “A”, indicating an acquisition from the issuer rather than an open-market purchase. The RSUs convert to common stock on a one-for-one basis and will vest on the earlier of (i) one year from the grant date or (ii) the day prior to Liquidia’s next annual shareholder meeting. Following the transaction, Dr. Horobin’s total beneficial ownership increased to 38,755 shares. No cash was exchanged (price reported as $0), and no derivative securities were involved beyond the RSU grant.
The filing represents routine annual director equity compensation and does not disclose any additional purchases, sales, or option exercises.
Liquidia Corp (LQDA) reported insider trading activity through a Form 4 filing dated June 28, 2025. Director Damian deGoa acquired 18,396 restricted stock units (RSUs) on June 17, 2025, which convert to common stock on a one-for-one basis.
Key transaction details:
- Transaction was executed at $0 price as part of equity compensation
- Following the transaction, deGoa directly owns 86,471 shares
- RSUs vest at earlier of one-year anniversary of grant date or day before next annual shareholder meeting
This equity grant appears to be part of the company's director compensation program, representing standard board member remuneration. The filing indicates no derivative securities transactions and confirms deGoa's position as a non-employee director without 10% ownership stake.
Liquidia Corporation (LQDA) – Form 4 insider transaction
Director Dr. Stephen M. Bloch reported the award of 18,396 restricted stock units (RSUs) on 17 June 2025. The RSUs convert into common stock on a one-for-one basis and will vest on the earlier of (i) one year from the grant date or (ii) the day prior to the company’s next annual shareholder meeting. Because the award was granted at $0 cost (typical director equity compensation), the filing shows an “A” transaction code (acquisition/grant).
Following the grant, Dr. Bloch’s direct beneficial ownership increased to 38,755 common shares. No open-market purchases, sales, or derivative transactions were reported, and no cash changed hands.
The filing signals routine board compensation rather than an active investment decision, but it modestly aligns the director’s interests with shareholders by increasing equity exposure.
FAQ
What is the current stock price of Liquidia Corporation (LQDA)?
What is the market cap of Liquidia Corporation (LQDA)?
What is Liquidia Corporation's core business?
How does PRINT® Technology enhance drug delivery?
Which therapeutic areas does Liquidia focus on?
How does Liquidia generate revenue?
What differentiates Liquidia from its competitors?
How does Liquidia ensure the quality and safety of its products?
What role do strategic partnerships play in Liquidia’s business model?
